ABSTRACT
Background Chronic kidney disease (CKD) is a genetically complex disease determined by an interplay of monogenic, polygenic, and environmental risks. Most forms of monogenic kidney diseases have incomplete penetrance and variable expressivity. It is presently unknown if some of the variability in penetrance can be attributed to polygenic factors.
Methods Using the UK Biobank (N=469,835 participants) and the All of Us (N=98,622 participants) datasets, we examined two most common forms of monogenic kidney disorders, autosomal dominant polycystic kidney disease (ADPKD) caused by deleterious variants in the PKD1 or PKD2 genes, and COL4A-associated nephropathy (COL4A-AN caused by deleterious variants in COL4A3, COL4A4, or COL4A5 genes). We used the eMERGE-III electronic CKD phenotype to define cases (estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2 or kidney failure) and controls (eGFR >90 mL/min/1.73m2 in the absence of kidney disease diagnoses). The effects of the genome-wide polygenic score (GPS) for CKD were tested in monogenic variant carriers and non-carriers using logistic regression controlling for age, sex, diabetes, and genetic ancestry.
Results As expected, the carriers of known pathogenic and rare predicted loss-of-function variants in PKD1 or PKD2 had a high risk of CKD (ORmeta=17.1, 95% CI: 11.1-26.4, P=1.8E-37). The GPS was comparably predictive of CKD in both ADPKD variant carriers (ORmeta=2.28 per SD, 95%CI: 1.55-3.37, P=2.6E-05) and non-carriers (ORmeta=1.72 per SD, 95% CI=1.69-1.76, P< E-300) independent of age, sex, diabetes, and genetic ancestry. Compared to the middle tertile of the GPS distribution for non-carriers, ADPKD variant carriers in the top tertile had a 54-fold increased risk of CKD, while ADPKD variant carriers in the bottom tertile had only a 3-fold increased risk of CKD. Similarly, the GPS was predictive of CKD in both COL4-AN variant carriers (ORmeta=1.78, 95% CI=1.22-2.58, P=2.38E-03) and non-carriers (OR =1.70, 95%CI: 1.68-1.73 P<E-300). The carriers in the top tertile of the GPS had a 2.5-fold higher risk of CKD while the risk for carriers in the bottom tertile was similar to the middle tertile of non-carriers.
Conclusions Variable penetrance of kidney disease in ADPKD and COL4-AN is partially explained by differences in polygenic risk profiles. Accounting for polygenic factors has the potential to improve risk stratification in monogenic kidney disease and may have implications for genetic counseling.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the National Human Genome Research Institute (NHGRI) Electronic Medical Records and Genomics-IV (eMERGE-IV grant 5U01HG008680-07), National Library of Medicine (NLM grant R01LM013061), National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK grant 5K25DK128563-03) and National Center for Advancing Translational Sciences (NCATS grant UL1TR001873). We are grateful to all participants from the UKBB and AoU projects for contributing their data and biological samples that enabled this study. The research on UK Biobank data has been conducted using the UK Biobank Resource under Application Number 41849. The All of Us Research Program is supported by the NIH Office of the Director through the following grants: Regional Medical Centers: 1OT2OD026549; 1OT2OD026554; 1OT2OD026557; 1OT2OD026556; 1OT2OD026550; 1OT2OD 026552; 1OT2OD026553; 1OT2OD026548; 1OT2OD026551; 1OT2OD026555; IAA# AOD16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5U2COD023196; Biobank: 1U24OD023121; The Participant Center: U24OD023176; Participant Technology Systems Center: 1U24OD023163; Communications and Engagement: 3OT2OD023205; 3OT2OD023206; and Community Partners: 1OT2OD025277; 3OT2OD025315; 1OT2OD025337; 1OT2OD025276.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflicts of Interest: None
Data Availability
The UKBB genotype and phenotype data are available through the UKBB web portal at https://www.ukbiobank.ac.uk/. The AoU genotype, WGS, and phenotype data are available through the AoU researcher workbench at https://www.researchallofus.org/data-tools/workbench/.
